Patent And Technology License Agreement Sample Contracts

Share Cite Term
Link

Embed (HTML)
Citius Pharmaceuticals, Inc. – Second Amendment to Patent and Technology License Agreement (May 15th, 2017)

This Second Amendment to Patent and Technology License Agreement (the "Amendment") is made as of the 20th day of March 2017 to the Patent and Technology License Agreement effective as of May 14, 2014, as amended (the "Agreement"), by and between Novel Anti-Infective Technologies, LLC (the "Licensor"), and Leonard-Meron Biosciences, Inc. ("Licensee"). Terms used herein that are not otherwise defined herein shall have the meanings given them in the Agreement.

AMENDMENT NO. 2 to AMENDED AND RESTATED PATENT AND TECHNOLOGY LICENSE AGREEMENT (May 10th, 2016)

This Amendment No. 2 to Amended and Restated Patent and Technology License Agreement (Amendment No. 2), effective as of March 25, 2016 (the Amendment No. 2 Effective Date), is entered into by and between Fred Hutchinson Cancer Research Center, a Washington state non-profit organization having offices at 1100 Fairview Avenue North, Seattle, Washington 98109 (FHCRC) and Juno Therapeutics, Inc., a Delaware corporation having offices located at 307 Westlake Avenue North, Suite 300, Seattle Washington 98109 (LICENSEE).

Amendment No. 1 to Amended and Restated Patent and Technology License Agreement (May 10th, 2016)

This Amendment No. 1 to Amended and Restated Patent and Technology License Agreement (the Amendment No. 1), effective as of October 22, 2015 (the Amendment No. 1 Effective Date), is entered into by and between Fred Hutchinson Cancer Research center, a Washington state non-profit organization having offices at 1100 Fairview Avenue North, Seattle, Washington 98109 (FHCRC), and Juno Therapeutics, Inc., a Delaware corporation having offices located at 307 Westlake Avenue North, Suite 300, Seattle, Washington 98019 (LICENSEE).

Amendment No. 1 to Amended and Restated Patent and Technology License Agreement (May 10th, 2016)

This Amendment No. 1 to Amended and Restated Patent and Technology License Agreement (the Amendment No. 1), effective as of October 22, 2015 (the Amendment No. 1 Effective Date), is entered into by and between Fred Hutchinson Cancer Research center, a Washington state non-profit organization having offices at 1100 Fairview Avenue North, Seattle, Washington 98109 (FHCRC), and Juno Therapeutics, Inc., a Delaware corporation having offices located at 307 Westlake Avenue North, Suite 300, Seattle, Washington 98019 (LICENSEE).

Moleculin Biotech, Inc. – Amendment No. 1 to the Patent and Technology License Agreement (March 22nd, 2016)

This AMENDMENT NO. 1 effective this 19th day of October, 2015 ("AMENDMENT NO. 1 EFFECTIVE DATE"), to the Patent and Technology License Agreement between the Parties dated April 2, 2012 ("ORIGINAL LICENSE"), is made by and between the BOARD OF REGENTS ("BOARD") of THE UNIVERSITY OF TEXAS SYSTEM ("SYSTEM"), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER (hereinafter "UTMDACC"), a member institution of SYSTEM, and INTERTECH BIO CORPORATION, a Texas corporation having a principal place of business located at 3910 Cypress Creek Parkway, Suite 100, Houston, Texas 77068 ("LICENSEE"). BOARD and LICENSEE may be referred to hereafter collectively as the "PARTIES."

Moleculin Biotech, Inc. – Patent and Technology License Agreement (March 22nd, 2016)

This AGREEMENT ("AGREEMENT") is made on this 2nd day of April, 2012, by and between THE BOARD OF REGENTS ("BOARD") of THE UNIVERSITY OF TEXAS SYSTEM ("SYSTEM"), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER ("UTMDACC"), a member institution of SYSTEM, and INTERTECH BIO CORPORATION, a Texas corporation having a principal place of business located at 3910 Cypress Creek Parkway, Suite 100, Houston, Texas 77068 ("LICENSEE").

Mri Interventions, Inc. – Patent and Technology License Agreement (March 22nd, 2016)

THIS PATENT AND TECHNOLOGY LICENSE AGREEMENT ("Agreement"), dated and effective as of April 4, 2016 ("Effective Date") is entered into by and among MRI Interventions, Inc., having a place of business at 5 Musick, Irvine, CA 92618 ("Licensor") and Brainlab AG, having a place of business at Kapellenstrasse 12, 85622 Feldkirchen, Germany ("Licensee").

Moleculin Biotech, Inc. – Patent and Technology License Agreement (March 22nd, 2016)

This AGREEMENT ("AGREEMENT") is made on this 21st day of June, 2010, by and between THE BOARD OF REGENTS ("BOARD") of THE UNIVERSITY OF TEXAS SYSTEM ("SYSTEM"), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER ("UTMDACC"), a component institution of SYSTEM, and Moleculin, LLC, a limited liability company organized and existing under the laws of the state of Texas, having a principal place of business located at 1973 West Clay, Houston, Texas 77019 ("LICENSEE").

Mri Interventions, Inc. – Patent and Technology License Agreement (March 22nd, 2016)

THIS PATENT AND TECHNOLOGY LICENSE AGREEMENT ("Agreement"), dated and effective as of April 4, 2016 ("Effective Date") is entered into by and among MRI Interventions, Inc., having a place of business at 5 Musick, Irvine, CA 92618 ("Licensor") and Brainlab AG, having a place of business at Kapellenstrasse 12, 85622 Feldkirchen, Germany ("Licensee").

Moleculin Biotech, Inc. – Amendment No. 1 to the Patent and Technology License Agreement (March 22nd, 2016)

This AMENDMENT NO. 1 effective this 19th day of October, 2015 ("AMENDMENT NO. 1 EFFECTIVE DATE"), to the Patent and Technology License Agreement between the Parties dated June 21, 2010 ("ORIGINAL LICENSE"), is made by and between the BOARD OF REGENTS ("BOARD") of THE UNIVERSITY OF TEXAS SYSTEM ("SYSTEM"), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER (hereinafter "UTMDACC"), a member institution of SYSTEM, and MOLECULIN, LLC, a limited liability company organized and existing under the laws of the state of Texas, having a principal place of business located at 1973 West Clay, Houston, Texas 77019 ("LICENSEE"). BOARD and LICENSEE may be referred to hereafter collectively as the "PARTIES."

Amendment No. 1 to Patent and Technology License Agreement (March 15th, 2016)

This Amendment No. 1 dated effective July 12, 2015 (the "Effective Date")amends the Patent and Technology License Agreement ("Agreement"), effective as of the 12th day of July, 2012 by and between Quick-Med Technologies, Inc., a Nevada corporation having offices at 902 NW 4 Street, Gainesville, Florida 32601 and Derma Sciences, Inc., a Delaware corporation having offices at 214 Carnegie Center, Suite 300, Princeton, New Jersey 08540 (each singularly a "Party" and collectively the "Parties").

SignPath Pharma, Inc. – Patent and Technology License Agreement (April 9th, 2015)

Simultaneously with the delivery of each such report, SIGNPATH agrees to pay UNTHSC the amount due; if any, for the period of such report. These reports are required even if no payments are due.

MultiVir Inc. – Amendment No. 1 to the Patent and Technology License Agreement (March 30th, 2015)

This is AMENDMENT NO. 1 effective this 1st day of September, 1996, (EFFECTIVE AMENDMENT NO. 1 DATE) to the Patent and Technology License Agreement dated July 20, 1994 (hereinafter referred to as the AGREEMENT), by and between THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (hereinafter referred to as MDA), located at Houston, Texas, and which is a component institution of THE UNIVERSITY OF TEXAS SYSTEM (hereinafter referred to as SYSTEM) which is governed by a BOARD OF REGENTS (hereinafter referred to as BOARD) and INTROGEN THERAPEUTICS, INC,. located at 301 Congress Avenue, Suite 1850, Austin, Texas 78701 (hereinafter referred to as LICENSEE).

MultiVir Inc. – Confidential Treatment Requested Confidential Portions of This Document Have Been Redacted and Have Been Separately Filed With the Securities and Exchange Commission Amendment No. 2 to the Patent and Technology License Agreement (March 30th, 2015)

This is AMENDMENT NO. 2 effective this 8 day of August, 1997, (EFFECTIVE AMENDMENT NO. 2 DATE) to the Patent and Technology License Agreement dated July 20, 1994, as amended by that certain Amendment No. 1 effective September 1, 1996 (HEREINAFTER REFERRED TO AS THE FIRST AMENDED AGREEMENT), by and between THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (hereinafter referred to as MDA), located at Houston, Texas, and which is a component institution of THE UNIVERSITY OF TEXAS SYSTEM (hereinafter referred to as SYSTEM) which is governed by a BOARD OF REGENTS (hereinafter referred to as BOARD) and INTROGEN THERAPEUTICS, INC., located at 301 Congress Avenue, Suite 1850, Austin, Texas 78701 (hereinafter referred to as LICENSEE).

MultiVir Inc. – Confidential Treatment Requested Confidential Portions of This Document Have Been Redacted and Have Been Separately Filed With the Securities and Exchange Commission Patent and Technology License Agreement (March 30th, 2015)

THIS AGREEMENT (AGREEMENT) is made by and between the BOARD OF REGENTS (BOARD) of THE UNIVERSITY OF TEXAS SYSTEM (SYSTEM), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (MDA), a component institution of the SYSTEM and INTRON THERAPEUTICS, INC., a Texas corporation having a principal place of business located at 301 Congress, Suite 2025, Austin, Texas 78701 (LICENSEE).

Greenhouse Solutions, Inc. – Patent and Technology License Agreement (January 22nd, 2015)

This twelve (12) page AGREEMENT ("AGREEMENT") is made on this 20th day of January, 2015 between DR. MALIREDDY S. REDDY ("DR. REDDY") whose address is c/o ADFAC/IMAC, 1250 S Parker Road, Suite 203, Denver, CO 80231-7559, and GREENHOUSE SOLUTIONS, INC. ("GREENHOUSE"), a Nevada corporation having a principal place of business located at 16359 County Rd S, Fort Morgan, CO 80701, and whose Colorado registered agent of record is Michael A. Littman, whose address is 7609 Ralston Road, Arvada, CO 80002.

MultiVir Inc. – Confidential Treatment Requested Confidential Portions of This Document Have Been Redacted and Have Been Separately Filed With the Securities and Exchange Commission Patent and Technology License Agreement (December 22nd, 2014)

THIS AGREEMENT (AGREEMENT) is made by and between the BOARD OF REGENTS (BOARD) of THE UNIVERSITY OF TEXAS SYSTEM (SYSTEM), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (MDA), a component institution of the SYSTEM and INTRON THERAPEUTICS, INC., a Texas corporation having a principal place of business located at 301 Congress, Suite 2025, Austin, Texas 78701 (LICENSEE).

MultiVir Inc. – Confidential Treatment Requested Confidential Portions of This Document Have Been Redacted and Have Been Separately Filed With the Securities and Exchange Commission Amendment No. 2 to the Patent and Technology License Agreement (December 22nd, 2014)

This is AMENDMENT NO. 2 effective this 8 day of August, 1997, (EFFECTIVE AMENDMENT NO. 2 DATE) to the Patent and Technology License Agreement dated July 20, 1994, as amended by that certain Amendment No. 1 effective September 1, 1996 (HEREINAFTER REFERRED TO AS THE FIRST AMENDED AGREEMENT), by and between THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (hereinafter referred to as MDA), located at Houston, Texas, and which is a component institution of THE UNIVERSITY OF TEXAS SYSTEM (hereinafter referred to as SYSTEM) which is governed by a BOARD OF REGENTS (hereinafter referred to as BOARD) and INTROGEN THERAPEUTICS, INC., located at 301 Congress Avenue, Suite 1850, Austin, Texas 78701 (hereinafter referred to as LICENSEE).

MultiVir Inc. – Amendment No. 1 to the Patent and Technology License Agreement (December 22nd, 2014)

This is AMENDMENT NO. 1 effective this 1st day of September, 1996, (EFFECTIVE AMENDMENT NO. 1 DATE) to the Patent and Technology License Agreement dated July 20, 1994 (hereinafter referred to as the AGREEMENT), by and between THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (hereinafter referred to as MDA), located at Houston, Texas, and which is a component institution of THE UNIVERSITY OF TEXAS SYSTEM (hereinafter referred to as SYSTEM) which is governed by a BOARD OF REGENTS (hereinafter referred to as BOARD) and INTROGEN THERAPEUTICS, INC,. located at 301 Congress Avenue, Suite 1850, Austin, Texas 78701 (hereinafter referred to as LICENSEE).

Amended and Restated Patent and Technology License Agreement (November 24th, 2014)

This AMENDED AND RESTATED PATENT AND TECHNOLOGY LICENSE AGREEMENT (AGREEMENT) is made on this 2nd day of January, 2012, by and between FRED HUTCHINSON CANCER RESEARCH CENTER (FHCRC), a Washington state nonprofit organization, with principal offices located at 1100 Fairview Ave. N., Seattle, Washington 98109, and ZetaRx BioSciences Inc., a Delaware corporation, having a principal place of business located at 307 Westlake Avenue North, Suite 300, Seattle, WA 98109 (LICENSEE).

Amended and Restated Patent and Technology License Agreement (November 24th, 2014)

This AMENDED AND RESTATED AGREEMENT (AGREEMENT) is made on October 16, 2013, by and between FRED HUTCHINSON CANCER RESEARCH CENTER (FHCRC), a Washington state nonprofit organization, with principal offices located at 1100 Fairview Ave. N., Seattle, Washington 98109, and JUNO THERAPEUTICS, INC., a Delaware corporation, having a principal place of business located at 307 Westlake Avenue North, Suite 300, Seattle Washington 98109 (LICENSEE).

Amended and Restated Patent and Technology License Agreement (November 24th, 2014)

This AMENDED AND RESTATED PATENT AND TECHNOLOGY LICENSE AGREEMENT (AGREEMENT) is made on this 1st day of November, 2009, by and between FRED HUTCHINSON CANCER RESEARCH CENTER (FHCRC), a Washington state nonprofit organization, with principal offices located at 1100 Fairview Ave. N., Seattle, Washington 98109, and ZETARX LLC, a Delaware limited liability company, having a principal place of business located at 9701 Wilshire Blvd. Suite 1000, Beverly Hills, CA 90212 (LICENSEE).

SunEdison Semiconductor Ltd – PATENT AND TECHNOLOGY LICENSE AGREEMENT (CCz & DCW Technology) (June 2nd, 2014)

This Patent and Technology License Agreement (Agreement), made and entered into as of May 27, 2014 and effective as of the Effective Date, is by and between SunEdison, Inc., a Delaware corporation (SunEdison), and SunEdison Semiconductor Limited, a company organized and existing under the laws of Singapore and having its registered office at 80 Robinson Road, #02-00, Singapore 068898 (SSL).

SunEdison Semiconductor Ltd – PATENT AND TECHNOLOGY LICENSE AGREEMENT (CCz & DCW Technology) (May 12th, 2014)

This Patent and Technology License Agreement (Agreement), made and entered into as of [] and effective as of the Effective Date, is by and between SunEdison, Inc., a Delaware corporation (SunEdison), and SunEdison Semiconductor Limited, a company organized and existing under the laws of Singapore and having its registered office at 80 Robinson Road, #02-00, Singapore 068898 (SSL).

ContraVir Pharmaceuticals, Inc. – First Amendment to Patent and Technology License Agreement (December 24th, 2013)

This First Amendment to Patent and Technology License Agreement (this Amendment) is effective as of March 27, 2007 (the Effective Date) and amends that certain Patent and Technology License Agreement dated as of February 2, 2005 (the License) by and between University College Cardiff Consultant Limited a company incorporated under the laws of England and Wales whose address in 30 36 Newport Road, Cardiff CF24 ODE, United Kingdom (UCT) and FermaVir Research, Inc. (formally known as ContraVir Research, Inc.), a Delaware corporation having an address of 420 Lexington Avenue, Suite 445, New York, NY 10170 (FermaVir).

Quick-Med Technologies – Contract (May 17th, 2013)
Quick-Med Technologies – AMENDMENT No. 4 to the PATENT AND TECHNOLOGY LICENSE AGREEMENT of July 26, 2010; The AMENDMENT NO. 1 of December 2, 2011; The AMENDMENT NO. 2 of April 5, 2012; And the AMENDMENT No. 3 of December 17, 2012 (May 17th, 2013)

This fourth amendment to the Patent and Technology License Agreement of July 26, 2010 ("Agreement") as amended by Amendment No.1 of December 2, 2011; Amendment No. 2 of April 5, 2012; and Amendment No. 3 of December 17, 2012 ("Previous Amendments") is by and between Quick-Med Technologies, Inc., a Nevada corporation having offices at 902 NW Fourth Street, Gainesville, Florida 32601 ("QMT") and Viridis BioPharma Pvt. Ltd., an India corporation having offices at 6/10 Jogani Industrial Complex, V.N. Purav Marg, Chunabatti, Mumbai - 400022 India ("VIRIDIS") (each singularly a "Party" and collectively the "Parties").

Bio-Path Holdings Inc – Patent and Technology License Agreement (May 15th, 2013)

This AGREEMENT ("AGREEMENT") is made oil this 2nd day of November, 2007, by and between THE BOARD OF REGENTS ("BOARD") of THE UNIVERSITY OF TEXAS SYSTEM ("SYSTEM"), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER ("UTMDACC"), a component institution of SYSTEM, and BIO-PATH, INC. a corporation having a principal place of business located at 3293 Harrison Boulevard, Suite 230, Ogden, Utah 84403 ("LICENSEE").

Bio-Path Holdings Inc – Amendment No. 1 to the Patent and Technology License Agreement (May 15th, 2013)

This AMENDMENT NO. 1 effective this 11th day of May, 2009 ("AMENDMENT NO. 1 EFFECTIVE DATE"), to the Patent and Technology License Agreement between the Parties dated November 2, 2007 (for MDA 94-036 and MDA 97-004) ("ORIGINAL LICENSE"), is made by and between the BOARD OF REGENTS ("BOARD") of THE UNIVERSITY OF TEXAS SYSTEM ("SYSTEM"), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER (hereinafter "UTMDACC"), a component institution of SYSTEM, and BIO-PATH, INC. a Utah corporation having a principal place of business located at 2939 Harrison Boulevard, Suite 230, Ogden, Utah, 84403 ("LICENSEE") BOARD and LICENSEE may be referred to hereafter collectively as the "PARTIES."

Patent and Technology License Agreement (April 1st, 2013)

THIS AGREEMENT is made as of this 31st day of December, 2012 (the "Effective Date"), by and between VERIFYME, INC., a Texas corporation ("LICENSOR") and LASERLOCK TECHNOLOGIES, INC., a Nevada corporation ("LICENSEE") (collectively the "Parties").

American Graphite Technologies Inc. – Schedule 2 to Patent and Technology License Agreement Dated December 3, 2012 (February 5th, 2013)

2- identify and purchase deposition, pump, & curing equipment. If new, this could cost over $40K for deposition and pumping equipment, curing equipment would be more.

American Graphite Technologies Inc. – Non-Exclusive Patent and Technology License Agreement for Patent and Trade Secret Technology in the Field of Graphene Oxide or "Bucky" Paper (December 18th, 2012)

This agreement ("This Agreement" ) is effective December 3, 2012 by and between Cheap Tubes, Inc., a Vermont corporation having principal offices at 112 Mercury Dr., Brattleboro, VT 05301 ("Cheap Tubes" or "Licensor"), and American Graphite Technologies Inc., a Nevada public Company having principal offices at 3651 Lindell Rd., Suite D#422, Las Vegas, Nevada 89103 ("AGT" or "Licensee"). Cheap Tubes and AGT may be collectively referred to hereinafter as "The Parties".

Global Mobiletech, Inc. – Amendment # 1 to Patent and Technology License Agreement Between Soon Hock Lim and Global Mobiletech, Inc. (October 24th, 2012)

This Amendment to that certain Patent and Technology License Agreement dated December 15, 2011, (the License Agreement), is made this 23rd day of March, 2012.

Global Mobiletech, Inc. – Amendment # 2 to Patent and Technology License Agreement Between Soon Hock Lim and Global Mobiletech, Inc. (October 24th, 2012)

This Agreement to that certain Amendment #1 dated March 23, 2012 (Amendment #1) to the Patent and Technology License Agreement dated December 15, 2011 (the License Agreement), is made this 1st day of June, 2012.

Quick-Med Technologies – Patent and Technology License Agreement (July 18th, 2012)

This Patent and Technology License Agreement ("Agreement"), effective as of the 12th day of July, 2012 (the "Effective Date"), is by and between Quick-Med Technologies, Inc., a Nevada corporation having offices at 902 NW 4 Street, Gainesville, Florida 32601 ("QMT") and Derma Sciences, Inc., a Pennsylvania corporation having offices at 214 Carnegie Center, Suite 300, Princeton, New Jersey 08540 ("DERMA") (each singularly a "Party" and collectively the "Parties").